Drug Profile
PL MLP
Alternative Names: LPMX-1; LPMX-2; PL-MLP; PromitilLatest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator Hebrew University of Jerusalem
- Developer Lipomedix Pharmaceuticals
- Class Antineoplastics; Carbamates; Cytostatic antibiotics; Disulfides; Mitomycins
- Mechanism of Action Alkylating agents; DNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Bladder cancer; Colorectal cancer; Gastrointestinal cancer; Solid tumours
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for phase-I development in Gastrointestinal-cancer(Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Israel (IV)
- 28 Feb 2023 No recent reports of development identified for phase-I development in Solid-tumours(Inoperable/Unresectable, Late-stage disease, Second-line therapy or greater) in Israel (IV, Infusion)
- 28 Feb 2023 No recent reports of development identified for preclinical development in Bladder-cancer in Israel (Intravesicular, Liquid)